Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Beam Therapeutics Appoints Eric Foster As Chief Commercial Officer

PUBLIC · BEAMSep 01, 2026•3 days ago

Position

Chief Commercial Officer

Company

Beam Therapeutics Inc.

Eric Foster
CambridgeBiotechnologyHealthcareHealth CareTherapeutics

Description

Beam Therapeutics has appointed Eric Foster as Chief Commercial Officer. With over 25 years of experience in biotechnology and specialty pharmaceuticals, Mr. Foster is set to play a crucial role in leading the company's commercial strategies as they prepare for future product launches.

Company Information

Company

Beam Therapeutics Inc.

Location

325 VASSAR STREET, SUITE 2A

Cambridge, Massachusetts, United States

About

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.

Don't miss Beam Therapeutics Inc.'s next move

Get an email the moment Beam Therapeutics Inc. changes its leadership, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Beam Therapeutics Inc.'s next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Beam Therapeutics Inc. changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.